Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia

Leukemia, Myeloid, Acute Clinical Trial

Official title:

The Feasibility of Safely Managing Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia (AML) in an Outpatient Environment

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03988205
• Other study ID #: PRO34597
• Status: Terminated
• Phase: Phase 4
• Start date: August 28, 2019
• Est. completion date: April 1, 2022

Study information

• Verified date: July 2022
• Source: Medical College of Wisconsin
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-arm, single-site run-in phase (six subjects) followed by a multicenter continuation phase (114 subjects), Phase IV study. Eligible subjects will be receiving CPX-351 as their usual medical care administered according to FDA approval, as a condition for participation.

Description:

This is an open-label, non-randomized study of a non-drug intervention in subjects receiving CPX-351 as their usual medical care administered according to its FDA approval. The study intervention is the application of a prescribed outpatient care model, including a nurse teacher educational program and quality of life surveys for both subjects and caregivers, in subjects who meet medical and logistical criteria. Induction therapy and medical follow-up are performed without prophylactic admission to an inpatient facility.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 3
• Est. completion date: April 1, 2022
• Est. primary completion date: December 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subjects with newly diagnosed acute myeloid leukemia who are eligible for treatment with CPX-351 therapy according to the FDA approval and indication: therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

2. Age = 18 years

3. Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1 (or Karnofsky Performance Status equivalent of 70 or above).

4. Total bilirubin = 3 mg/dL.

5. Creatinine clearance > 30 mL/min by Cockcroft/Gault equation.

6. Adequate cardiac function, as assessed by ejection fraction( =50% for anthracycline therapy) via multiple-gated acquisition (MUGA) or echocardiogram.

7. Total white blood cell count of = 20,000/µL on peripheral blood assessment (hydrea and/or leukapheresis allowed).

8. No evidence of active, uncontrolled infection.

9. No evidence of clinically significant disseminated intervascular coagulation (DIC)

10. No clinically significant abnormalities in core vital signs like heart rate, blood pressure or oxygenation which require inpatient evaluation or monitoring.

11. In the opinion of the enrolling physician, the subject is not at risk for clinically significant tumor lysis syndrome based on clinical assessment, complete blood count (CBC), comprehensive metabolic panel (CMP), uric acid, and lactate dehydrogenase (LDH).

12. In the opinion of the enrolling physician, no medical conditions that preclude the subject or the primary caregiver from transportation to and from the outpatient clinical care facility.

13. Both subject and the identified primary caregiver(s) signed informed consent.

14. In the opinion of the enrolling physician, there are no medical contraindications to outpatient induction and management.

15. Male subjects, even if surgically sterilized (i.e., status post vasectomy), must agree to one of the followings:

• Practice effective barrier contraception during the entire study period and through six months after the last dose of CPX-351, OR

• Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable methods of contraception.)

Female subjects must meet one of the followings:

• Postmenopausal for at least one year before enrollment, OR

• Surgically sterile (i.e., undergone a hysterectomy or bilateral oophorectomy), OR

• If the subject is of childbearing potential (defined as not satisfying either of the above two criteria), she must agree to practice two acceptable methods of contraception (combination methods require use of two of the following: diaphragm with spermicide, cervical cap with spermicide, contraceptive sponge, male or female condom, hormonal contraceptive) from the time of signing of the informed consent form through six months after the last dose of CPX-351, OR o Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable contraception methods.)

Logistical Inclusion Criteria

1. The subject must be able to reside within approximately 45 minutes of the hospital where induction therapy is administered, during normal driving conditions (in the opinion of the enrolling physician), until count recovery or 60 days post-treatment, whichever comes first

2. The enrolling physician must verify and attest that the subject has a primary caregiver meeting all the following criteria:

• Reside with the subject.

• Be able to care for the subject full time or arrange to share full-time care with secondary caregivers.

• Provide transportation.

• Respond to clinical issues that arise.

• Communicate with subject and physician in a timely manner.

3. The nurse teacher must verify that the subject and primary caregiver have completed and adequately understand the study-dictated nurse teacher educational program.

4. The nurse teacher must verify the subject and primary caregiver have capacity to comply with outpatient management program.

5. The subject must have reliable, working telephone access.

6. The subject must be willing and able to attend all protocol-dictated visits and be seen frequently as an outpatient at the clinical care facility where induction therapy is administered.

Exclusion Criteria:

1. Pregnant women (per pregnancy test in women of childbearing potential) or women who are breast-feeding.

2. Subjects currently receiving any investigational agents.

3. Subjects must not have current evidence of another malignancy that requires treatment.

4. Subjects diagnosed with Wilson's disease and/or copper-related metabolic disorders.

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute

Intervention

Behavioral:
• Outpatient Care Model
Outpatient care model includes a nurse teacher educational program, scheduled outpatient visit protocol, and quality of life surveys for both subjects and caregivers.

Drug:
• CPX-351
CPX-351 is administered, according to FDA approval, to subjects who meet medical and logistical criteria for study enrollment.

Locations

Country	Name	City	State
United States	Froedtert Hospital	Milwaukee	Wisconsin

Sponsors (1)

Lead Sponsor	Collaborator
Medical College of Wisconsin

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants Adherent to Recommendations	This measure will record the number subjects who adhere to outpatient follow-up appointments and readmission recommendations. Subjects completing 95% of their recommended outpatient visits will be considered to be adherent to the recommendations.	Day 60
Primary	Number of Participants Adherent to Readmission Recommendations	This measure will record the number of subjects who complete as 100% compliance with medical provider recommendations to be admitted to the hospital (except for reasons of adopting a palliative or hospice approach to care). Subjects not achieving a 100% rate of compliance will be considered non-adherent to the recommendations.	Day 60